Copyright
©2006 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Sep 21, 2006; 12(35): 5692-5698
Published online Sep 21, 2006. doi: 10.3748/wjg.v12.i35.5692
Published online Sep 21, 2006. doi: 10.3748/wjg.v12.i35.5692
Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: Impact of bilharziasis and fibrosis stage
MF Derbala, SR Al Kaabi, NZ El Dweik, F Pasic, MT Butt, R Yakoob, Department of Gastroenterology and Hepatology, Hamad Medical Corporation, Doha, Qatar
A Al-Marri, Department of Immunology, Hamad Medical Corporation, Doha, Qatar
AM Amer, Department of Haematology, Hamad Medical Corporation, Doha, Qatar
N Morad, Department of Histopathology, Hamad Medical Corporation, Doha, Qatar
A Bener, Department of Medical Statistics and Epidemiology, Hamad Medical Corporation, Doha, Qatar
Author contributions: All authors contributed equally to the work.
Correspondence to: Professor Moutaz Derbala, Department of Gastroenterology and Hepatology, Hamad Medical Corporation, Doha, Qatar. mod2002@qatar-med.cornell.edu
Telephone: +974-4392439 Fax: +974-4392271
Received: April 17, 2006
Revised: May 15, 2006
Accepted: May 22, 2006
Published online: September 21, 2006
Revised: May 15, 2006
Accepted: May 22, 2006
Published online: September 21, 2006
Core Tip